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Azole resistance is an emerging increasing problem in Aspergillus fumigatus that results in treatment failure. Alternative treat-
ments may improve the therapeutic outcome in patients with azole-resistant invasive aspergillosis (IA). Little is known about the
in vivo efficacy of the echinocandin anidulafungin (AFG) in IA. The in vivo efficacy of 2.5, 5, 10, and 20 mg/kg of body weight
AFG was assessed against two clinical Aspergillus fumigatus isolates with identical AFGminimum effective concentrations
(MECs; 0.03 mg/liter) in a murine model of IA: a wild-type voriconazole (VCZ)-susceptible (VCZs) A. fumigatus isolate (AZN
8196) and a VCZ-resistant (VCZr) A. fumigatus isolate (V52-35) harboring the TR34/L98H resistance mechanism (substitution at
codon L98 in combination with a 34-bp tandem repeat in the promoter region of the CYP51A gene). The pharmacokinetics of
AFG were also assessed for each dose. Increasing doses increased survival for both isolates in a manner dependent on the AFG
dose level (R2 0.99 and 0.95, respectively) up to a maximum of 72.7% and 45.45% for the VCZs and VCZr isolates, respectively.
The area under the concentration-time curve (AUC) correlated significantly with the dose in a linear fashion over the entire dos-
ing range (R2 0.86). The Hill equation with a variable slope fitted the relationship between the 24-h AUC/MEC ratio and 14-
day survival well (R2 0.87; P< 0.05). The 50% effective AUC/MEC for total AFG was 126.5 (95% confidence interval, 79.09 to
202.03). AFG treatment improved the survival of mice in a dose-dependent manner; however, a maximal response was not
achieved with either isolate even in those treated with the highest AFG dose.
Aspergillus fumigatus may cause life-threatening infections inboth immunocompetent and immunocompromised patients
(1–3). Voriconazole (VCZ) is considered the first choice of ther-
apy for invasive aspergillosis (IA) (4, 5). However, the rate of azole
resistance is increasing in A. fumigatus, which significantly com-
plicates the management of IA, as azole resistance is associated
with therapeutic failure and a mortality rate of up to 88% (6–13).
Primary invasive infections due to resistant isolates involving the
lung (13, 14), bone (15) and brain (14, 16) have been reported, as
have respiratory isolates in patients with allergic bronchopulmo-
nary aspergillosis (7). Seventy-nine percent of isolates with the
TR34/L98H mutation are VCZ resistant (VCZ
r), and this mutation
is the most prevalent resistance mechanism in clinical isolates
(11). All patients with pulmonary aspergillosis due to TR34/L98H
mutant isolates who received VCZ monotherapy died by the 12th
week of therapy (11). Therefore, it is important to explore alter-
native treatment regimens, as alternative treatments may improve
the therapeutic outcome in patients with azole-resistant IA.
Anidulafungin (AFG) belongs to the echinocandins but has a
unique site of action different from that of azoles and polyenes, as
it targets cell wall synthesis, and has fungistatic activity against
Aspergillus spp., in addition to an excellent safety profile (17–19).
Little is known about the in vivo efficacy of the echinocandin AFG
in IA.
Here we investigated the pharmacokinetic (PK)-pharmacody-
namic (PD) properties of AFG in a nonneutropenic murine model
of IA. For this purpose, we used two clinical isolates with different
profiles of susceptibility to voriconazole: a VCZ-susceptible
(VCZs) A. fumigatus isolate and a VCZr A. fumigatus isolate har-
boring a TR34/L98H mutation in the cyp51A gene.
(Parts of these results were presented at the 51st Interscience
Conference on Antimicrobial Agents and Chemotherapy, Chi-
cago, IL, 17 to 20 September 2011.)
MATERIALS AND METHODS
Fungal isolates. Two clinical A. fumigatus isolates obtained from patients
with proven IA were used in the experiments: a VCZs isolate without
mutations in the cyp51A gene (AZN 8196) and a VCZr isolate (V52-35)
harboring the TR34/L98H resistance mechanism. Strain identifications
and the cyp51A gene substitutions were confirmed by sequence-based
analysis as described previously (9). The isolates had been stored in 10%
glycerol broth at80°C and were revived by subculturing on Sabouraud
dextrose agar (SDA) supplemented with 0.02% chloramphenicol for 5 to
7 days at 35 to 37°C. The in vitro antifungal susceptibility test was per-
formed on the basis of EUCAST guidelines, using a broth microdilution
format (20).
Infectionmodel. A total of 170 outbred female CD-1 mice (age, 4 to 5
weeks; weight, 20 to 25 g; Charles River, the Netherlands) were random-
ized into groups of 17 mice for AFG monotherapy. Animals were infected
using the procedure described before (21, 22). Before performing the
experiment, the isolates were cultured once on SDA for 7 days at 35 to
37°C and subcultured twice on 15-cm Takashio slants for 5 days at 35 to
37°C. The conidia were harvested in 20 ml of sterile phosphate-buffered
saline (PBS) plus 0.1% Tween 80 (Boom B.V. Meppel, the Netherlands).
The conidial suspension was filtered through sterile gauze folded four
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times to remove any hyphae, and the number of conidia was counted in a
hemocytometer. After the inoculum was adjusted to the required concen-
tration, the conidial suspension was stored overnight at 4°C. The 90%
lethal dose (LD90) was separately determined for each isolate. Mice were
infected via injection into the lateral tail vein of an inoculum correspond-
ing to the LD90 of each isolate. The LD90s of VCZ
s and VCZr (TR34/L98H
mutant)A. fumigatus isolates used in the current study were 2.4 107 and
2.5  107 conidia, respectively. Postinfection viability counts of the in-
jected inocula were determined to ensure that the correct inoculum had
been injected.
The animals were housed under standard conditions, with drink and
feed supplied ad libitum. The animal studies were conducted in accor-
dance with the recommendations of the European Community (Directive
86/609/EEC, 24 November 1986), and all animal procedures were ap-
proved by the Animal Welfare Committee of Radboud University
(RU-DEC 2010-187). The infected mice were examined at least three
times daily. These clinical inspections were carried out in order to ensure
that there were no cases of desiccation, torticollis, staggering, high weight
loss (a decrease of 15% within 48 h or 20% within 24 h), or body temper-
ature drop to below 33°C. Mice demonstrating these signs of disease were
humanely terminated. On day 15 postinfection, all remaining surviving
mice were humanely euthanized under isoflurane anesthesia, and blood
and internal organs were collected. The survival (in number of days
postinfection) was recorded for each mouse in each group and was the
outcome effect measure used to assess the therapeutic efficacy of AFG
monotherapy (23).
Antifungal compound and treatment regimens. Treatment groups
consisted of AFG (Pfizer, Capelle a/d IJssel, the Netherlands) mono-
therapy at 2.5, 5, 10, 20, and 40 mg/kg of body weight/day. Intraperitoneal
therapy was begun at 24 h postinfection for 7 consecutive days and was
given once daily with standard daily dosing, in addition to a single loading
dose of AFG. The control group received single doses of saline.
Pharmacokinetic analysis of AFG in mice. A total of 144 outbred
female CD-1 mice (age, 4 to 5 weeks; weight, 20 to 22 g; Charles River, the
Netherlands) were used for separate PK experiments. On day 0, mice were
infected with the wild-type A. fumigatus isolate through the lateral tail
vein, and after 24 h, treatment was initiated, as described above, at dosages
of 5, 10, 20, and 40 mg/kg AFG. At day 2 of treatment (day 3 after infec-
tion), blood samples were drawn through an orbital vein or by heart
puncture and placed into lithium-heparin-containing tubes at 12 pre-
defined time points: immediately before administration of drugs and sub-
sequently at 0, 0.5, 1, 2, 4, 8, 12, 16, 20, 24, 48, and 72 h postdose. Blood
samples were cooled and centrifuged for approximately 10 min at 1,000
g within 30 min of collection. Plasma was aspirated, transferred into two
2-ml plastic tubes, and stored at80°C.
Analytical assay of anidulafungin.Anidulafungin samples were mea-
sured by ultraperformance liquid chromatography (UPLC) with fluores-
cence detection. Samples were pretreated using a protein precipitation
procedure (acetonitrile-methanol [50/50] and formic acid [0.1%]). A sev-
en-point calibration curve with three quality control samples was used. All
measurements were done in duplicate. The dynamic range of the assay was
0.008 to 8.4 mg/liter, and the accuracy range (n 15), which was depen-
dent on the concentration, was 94.2% to 103.5%. The intraday precision
varied between 0.9% and 1.8%, and the interday precision was between
0.5% and 1.6%. Validation in mouse plasma was over the dynamic range
of 0.008 mg/liter to 5.9 mg/liter. The intraday precision varied between
101.0% and 104.8%. Three freeze-thaw cycles did not impact the stability
of anidulafungin. Geometric mean concentrations of AFG in plasma from
three mice were separately calculated per time point. Maximum concen-
trations in plasma (Cmax) were directly observed from the data. Pharma-
cokinetic parameters were derived using noncompartmental analysis with
WinNonLin, version 5.2, software (Pharsight, Inc.). The area under the
plasma concentration-time curve (AUC) from time zero to 24 h postin-
fusion (AUC0-24) was determined by use of the log-linear trapezoidal rule.
The elimination rate constant was determined by linear regression of the
terminal points of the log-linear plasma concentration-time curve. The
terminal half-life was defined as ln 2 divided by the elimination rate con-
stant. Clearance (CL) was calculated as dose/AUC0-24.
Statistical analysis. All data analyses were performed by using Graph-
Pad Prism, version 5.0, software for Windows (GraphPad Software, San
Diego, CA). A regression analysis was conducted to determine the linear-
ity between dose and AUC. Mortality data were analyzed by the log rank
test. The survival data were plotted against the dose/minimum effective
concentration (MEC), and the Hill equation with a variable slope was
fitted to the data both for each individual isolate and for pooled survival
data. The goodness of fit was checked by use of the R2 value and visual
inspection. Statistical significance was defined as a P value of0.05 (two-
tailed). Dose/MEC and AUC0 –24/MEC ratios were calculated by dividing
the dose (in milligrams per kilogram of body weight) or AUC by the MEC.
Dose/MEC and AUC0 –24/MEC ratio data were log10 transformed to ap-
proximate a normal distribution prior to statistical analysis.
RESULTS
In vitro susceptibility. The characteristics and in vitro suscepti-
bility of the two selectedA. fumigatus isolates are shown in Table 1.
Both isolates grew well after 48 h of incubation at 35 to 37°C. VCZ
showed reduced in vitro activity against the TR34/L98H mutant
isolate, with a VCZ MIC of 4 mg/liter for the TR34/L98H mutant
isolate compared to one of 0.25 mg/liter for the wild-type isolate.
There was no difference in AFG activity, and both isolates had
identical MECs.
Pharmacokinetics of AFG. A total of 144 mice (3 mice per
time point, 12 time points, 4 different dosages) were analyzed. All
144 mice were alive at the time of sample collection. The observed
plasma concentration-versus-time profiles of AFG are shown in
Fig. 1. The corresponding pharmacokinetic parameters are tabu-
lated in Table 2. The AUC normalized to a dose of 2.5 mg/kg
resulted in ratios of 18.06, 18.6, 14.1, 16.3, and 20.1 for dosages of
2.5, 5, 10, 20, and 40 mg/kg, respectively. The AUC correlated
significantly with the dose in a linear fashion over the entire dosing
range (R2 0.86).
Efficacy of AFG monotherapy. (i) Survival curves. The sur-
vival curves for all control groups receiving saline intraperitone-
ally showed a mortality of 90 or 100% and a median survival time
of 3.5 to 4 days (Fig. 2). For both isolates, a dose-response rela-
TABLE 1 Origin, in vitro susceptibilities, and underlying azole resistance mechanisms of VCZs and VCZr A. fumigatus isolates
A. fumigatus isolatea
Cyp51A
substitution
MIC (mg/liter)
Anidulafungin MEC
(mg/liter)Amphotericin B Posaconazole Voriconazole
AZN 8196 None 0.5 0.031 0.25b 0.031
V52-35 TR34/L98H 0.5 0.5 4
c 0.031
a The A. fumigatus isolates were from patients with proven invasive aspergillosis.
b Susceptible.
c Resistant.
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tionship with increasing survival with increasing dose was ob-
served.
The maximum dose of AFG resulted in 72.7% survival in mice
infected with the VCZs isolate, whereas it resulted in 45.45% sur-
vival in mice infected with the VCZr isolate. Of note, the response
was lower in those infected with the VCZr isolate than the VCZs
isolate for each dose (Fig. 2).
(ii) Dose-response analysis. The dose-response curves for the
dosing regimen and control groups of AFG monotherapy are
shown in Fig. 3. AFG treatment improved the survival of the mice
in a dose-dependent manner. The dose-response curve for mice
infected with the VCZr isolate was shifted to the right compared to
that for mice infected with the VCZs isolate, indicating that higher
doses of AFG were required to achieve similar efficacy. In mice
receiving AFG monotherapy, a maximal response could not be
achieved with either isolate, even in those treated with the highest
AFG dose.
(iii) Exposure-response analysis. The AUC for each dose, de-
termined from PK experiments (Table 2), was used to calculate
the AUC0 –24/MEC ratio for each isolate, as shown in Fig. 4. The
exposure-response relationship had a sigmoidal shape. Increased
AFG exposure was required to obtain maximum efficacy in mice
infected with the VCZr isolate compared to those infected with the
VCZs isolate. The Hill equation with a variable slope fitted the
relationship between the 24-h AUC/MEC ratio and 14-day sur-
vival well (r2 0.87), as statistically significant pharmacodynamic
indices (PDIs) for single-agent regimens (P  0.05). The 50%
effective AUC for AFG was 126.5 (95% confidence interval, 79.09
to 202.03). We also determined the relationship between the in
vivo efficacy and other PDIs, such as the cumulative percentage of
a 24-h period that the drug concentration exceeded the MIC un-
der steady-state PK conditions and the peak level (Cmax)/MEC
(data not shown). However, AUC0-24/MEC appeared to be the
most important pharmacodynamic index correlating with effi-
cacy.
DISCUSSION
Our animal model indicated that AFG monotherapy is moder-
ately effective against isolates with a VCZ MIC within the suscep-
tible range and in groups of mice infected with the resistant TR34/
L98H mutant isolate, which had a VCZ MIC of 4 mg/liter.
Although increasing doses increased survival in a dose-dependent
manner, a maximal response was not achieved with either isolate,
even in those treated with the highest AFG dose (20 mg/kg of body
FIG 1 Plasma concentrations of anidulafungin following intraperitoneal administration of 5, 10, 20, and 40 mg/kg to immunocompetent infected mice. Each
symbol corresponds to the geometric mean and standard error of the mean plasma levels for three mice.
TABLE 2 Pharmacokinetic parameters of anidulafungin after intraperitoneal administration of various doses of AFGa
Dose
(mg/kg)
AUC0–24
(mg · h/liter)
Dose-normalized AUC
[(mg · h)/(liter · kg)] Tmax (h)
Cmax
(mg/liter)
Cmin
(mg/liter)
CLss/F [liter/
(h · kg)] t1/2 (h)
2.5 46.5b 18.6b
5 93 18.6 8 7.9 0.82 0.05 17.3448
10 141.4 14.1 2 10.7 3.3 0.07 17.3849
20 326.3 16.3 0.5 22.2 6.4 0.06 22.7847
40 802.7 20.1 4 49.5 20.7 0.05 15.3336
a AFG doses of 2.5 to 40 mg/kg were used. Intraperitoneal therapy was begun at 24 h postinfection with standard daily dosing of AFG, in addition to a single loading dose of AFG.
Tmax, time to Cmax; Cmin, minimum concentration in plasma; CLss/F, apparent steady-state clearance; t1/2, half-life.
b Simulated analysis of pharmacokinetic assay with concentrations ranging from 5 to 40 mg/kg.
PKs/PDs of AFG
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weight). Apparently, this explains why AFG is not effective as sin-
gle-drug therapy against Aspergillus infections, whereas VCZ is
(24), confirming that AFG is a less potent drug for the treatment of
IA (21, 22). A higher dose (40 mg/kg) of AFG was also studied for
some groups in order to achieve higher efficacy; however, a dose-
limiting toxicity was defined, and thus, we were not able to explore
the effect of higher doses.
Of note, AFG appeared to be slightly less effective against the
VCZr isolate than the VCZs isolate, despite identical MECs, which
raises a possible concern regarding the efficacy of anidulafungin
monotherapy for azole-resistant IA. Although this difference
could be due to differences in the virulence of the two isolates, we
have no indications that this is the case, as we have used this isolate
in our previous animal models, and the LD90 inocula were almost
identical (2.4  107 versus 2.5  107 conidia). We also investi-
gated the fitness of both isolates using a growth kinetic system (25)
but found no differences in germination times or growth rates
(results not shown). An alternative possibility might be that
changes in ergosterol biosynthesis through mutations in the
cyp51A gene might have indirect effects on fungal cell wall synthe-
sis. These changes might not be reflected in in vitro susceptibility,
as the MEC may not be sufficiently sensitive to detect subtle dif-
ferences in echinocandin drug activity. Further research into this
phenomenon is needed through, for instance, determination of
the levels of the glucan synthase target enzyme in azole-resistantA.
fumigatus isolates. A range of resistance mechanisms should be
investigated, as the effect on the cell wall might differ depending
on the underlying mutations.
The exposure-response relationship of AFG indicated that im-
provement of survival for both VCZs and VCZr isolates was de-
FIG 2 Efficacy of anidulafungin monotherapy against voriconazole-susceptible (MIC, 0.25 mg/liter) and voriconazole-resistant (MIC, 4 mg/liter) A. fumigatus
isolates. Both isolates had the same AFG MEC (0.03 mg/liter). Control groups received saline. For all groups, n 11.
FIG 3 Anidulafungin dose-survival relationships for voriconazole-suscepti-
ble and voriconazole-resistant A. fumigatus isolates. The curves indicate fits
with the Hill equation for each isolate.
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pendent on the dose, and since the dose-AUC relationship was
linear for the doses studies, this was also the case for the AUC0-24/
MEC ratio. The latter has relevance for predicting therapeutic
efficacy (26).
In the present study, the AUC of total AFG was relatively high
(326 mg · h/liter for the 20-mg/kg dose) and the MECs were quiet
low (0.03 mg/liter), so that AFG treatment alone does not result in
100% survival. The major factor here is that AFG is highly protein
bound, with protein binding estimated to be 99% (27) or possibly
more. The AUC for the free, unbound fraction of AFG (fAUC)/
MEC is therefore about 100 or even lower. The exact amount of
free drug is not well-known, however, since protein binding at
these high values is difficult to measure (27).
For echinocandins such as AFG, the 24-h fAUC/MIC ratio is
considered the PK/PD index determining therapeutic efficacy, as
indicated previously (26, 28). In humans, the AUC after a stan-
dard dose is slightly over 100 mg · h/liter (28, 29). Andes et al.
found that a fAUC0-24/MEC value of 100 was required to result in
a static effect in a Candida infection model (27). This value is
somewhat higher than the value found for other echinocandins,
indicating that 99% protein binding may be an underestimation.
van de Sande et al. reported only 18% survival of rats with IA after
administration of AFG at human-equivalent doses. In this study,
the steady-state fAUC0-24 for AFG was calculated to be 120.3 g ·
h/ml (29). Our results for AFG monotherapy at those values are in
line with those reports. We also used higher doses, however, which
resulted in increased survival of mice, although it did not reach
100%.
A possible limitation of the model used to explore the PK/PD
relationships is that the effects were observed in nonneutropenic
animals and the route of infection was dissemination rather than
inhalation. However, IA in the nonneutropenic host is observed
with increasing frequency, although other host factors might be
impaired in such patients, in particular, those in an intensive care
unit (3). The effects observed could therefore be an underestima-
tion of the exposure required. On the other hand, studies with
posaconazole and voriconazole in neutropenic (30) and nonneu-
tropenic (21, 22) models have shown that the exposure-response
relationships are of the same order of magnitude; in fact, slightly
lower exposures were required in the neutropenic model.
With respect to the discussion presented above, the AUC0-24/
MEC appeared to be the most important pharmacodynamic in-
dex, which can be used to predict the outcome of AFG mono-
therapy. However, compared to the results of our previous study
describing the pharmacodynamics of voriconazole monotherapy
(24), the results of the present study indicate that AFG is less
potent for the treatment of IA. Therefore, instead of using AFG
monotherapy for IA, other treatment modalities including this
agent in combination therapy can be useful approaches in the
clinical setting to improve the therapeutic outcomes of patients
with underlying IA. AFG belongs to the echinocandins, has a
unique site of action, as it targets cell wall synthesis, and has fun-
gistatic activity against Aspergillus spp. (18). The echinocandin
AFG offers a particularly interesting option for combination an-
tifungal therapy because of its mechanism of action, which is com-
pletely different from that of azoles and polyenes, and such com-
binations should be explored (17, 19). In addition, clinical studies
have suggested that combinations of echinocandins with other
antifungals are safe and may improve the response in patients with
IA (17). However, preclinical studies and the results of a multi-
center trial investigating such combinations will provide more
data to judge this strategy.
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